Nurix Therapeutics (NRIX) EPS (Basic): 2019-2025
Historic EPS (Basic) for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$1.03.
- Nurix Therapeutics' EPS (Basic) fell 53.73% to -$1.03 in Q3 2025 from the same period last year, while for Aug 2025 it was -$2.97, marking a year-over-year decrease of 2.06%. This contributed to the annual value of -$2.88 for FY2024, which is 8.68% down from last year.
- Latest data reveals that Nurix Therapeutics reported EPS (Basic) of -$1.03 as of Q3 2025, which was down 98.08% from -$0.52 recorded in Q2 2025.
- Nurix Therapeutics' EPS (Basic)'s 5-year high stood at -$0.45 during Q2 2023, with a 5-year trough of -$1.03 in Q3 2025.
- Over the past 3 years, Nurix Therapeutics' median EPS (Basic) value was -$0.71 (recorded in 2024), while the average stood at -$0.71.
- Within the past 5 years, the most significant YoY rise in Nurix Therapeutics' EPS (Basic) was 82.00% (2021), while the steepest drop was 393.18% (2021).
- Over the past 5 years, Nurix Therapeutics' EPS (Basic) (Quarterly) stood at -$0.85 in 2021, then declined by 1.18% to -$0.86 in 2022, then climbed by 10.47% to -$0.77 in 2023, then grew by 2.60% to -$0.75 in 2024, then crashed by 53.73% to -$1.03 in 2025.
- Its last three reported values are -$1.03 in Q3 2025, -$0.52 for Q2 2025, and -$0.67 during Q1 2025.